GIKLY
Price
$6.16
Change
+$0.15 (+2.50%)
Updated
Nov 12 closing price
Capitalization
7.88B
60 days until earnings call
Intraday BUY SELL Signals
GRFS
Price
$9.10
Change
+$0.07 (+0.78%)
Updated
Dec 26 closing price
Capitalization
7.88B
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GIKLY vs GRFS

Header iconGIKLY vs GRFS Comparison
Open Charts GIKLY vs GRFSBanner chart's image
Grifols Sa
Price$6.16
Change+$0.15 (+2.50%)
Volume$130
Capitalization7.88B
Grifols SA
Price$9.10
Change+$0.07 (+0.78%)
Volume$247.42K
Capitalization7.88B
GIKLY vs GRFS Comparison Chart in %
GIKLY
Daily Signal:
Gain/Loss:
GRFS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
GIKLY vs. GRFS commentary
Dec 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GIKLY is a Hold and GRFS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 28, 2025
Stock price -- (GIKLY: $6.16 vs. GRFS: $9.10)
Brand notoriety: GIKLY and GRFS are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GIKLY: 97% vs. GRFS: 38%
Market capitalization -- GIKLY: $7.88B vs. GRFS: $7.88B
GIKLY [@Pharmaceuticals: Major] is valued at $7.88B. GRFS’s [@Pharmaceuticals: Major] market capitalization is $7.88B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $964.61B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $104.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GIKLY’s FA Score shows that 1 FA rating(s) are green whileGRFS’s FA Score has 1 green FA rating(s).

  • GIKLY’s FA Score: 1 green, 4 red.
  • GRFS’s FA Score: 1 green, 4 red.
According to our system of comparison, both GIKLY and GRFS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GIKLY’s TA Score shows that 3 TA indicator(s) are bullish while GRFS’s TA Score has 4 bullish TA indicator(s).

  • GIKLY’s TA Score: 3 bullish, 0 bearish.
  • GRFS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, GIKLY is a better buy in the short-term than GRFS.

Price Growth

GIKLY (@Pharmaceuticals: Major) experienced а 0.00% price change this week, while GRFS (@Pharmaceuticals: Major) price change was +0.89% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.12%. For the same industry, the average monthly price growth was +1.24%, and the average quarterly price growth was +14.71%.

Reported Earning Dates

GIKLY is expected to report earnings on Feb 26, 2026.

GRFS is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+1.12% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GIKLY($7.88B) and GRFS($7.88B) have the same market capitalization . GIKLY has higher P/E ratio than GRFS: GIKLY (19.08) vs GRFS (14.11). GIKLY YTD gains are higher at: 32.514 vs. GRFS (24.374). GIKLY (1.63B) and GRFS (1.63B) have comparable annual earnings (EBITDA) . GIKLY (825M) and GRFS (825M) have equal amount of cash in the bank . GIKLY (8.82B) and GRFS (8.82B) have identical debt. GIKLY (7.52B) and GRFS (7.52B) have equivalent revenues.
GIKLYGRFSGIKLY / GRFS
Capitalization7.88B7.88B100%
EBITDA1.63B1.63B100%
Gain YTD32.51424.374133%
P/E Ratio19.0814.11135%
Revenue7.52B7.52B100%
Total Cash825M825M100%
Total Debt8.82B8.82B100%
FUNDAMENTALS RATINGS
GIKLY vs GRFS: Fundamental Ratings
GIKLY
GRFS
OUTLOOK RATING
1..100
5013
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
20
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7979
PRICE GROWTH RATING
1..100
5753
P/E GROWTH RATING
1..100
9495
SEASONALITY SCORE
1..100
5038

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GRFS's Valuation (20) in the Pharmaceuticals Major industry is in the same range as GIKLY (24) in the null industry. This means that GRFS’s stock grew similarly to GIKLY’s over the last 12 months.

GRFS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as GIKLY (100) in the null industry. This means that GRFS’s stock grew similarly to GIKLY’s over the last 12 months.

GRFS's SMR Rating (79) in the Pharmaceuticals Major industry is in the same range as GIKLY (79) in the null industry. This means that GRFS’s stock grew similarly to GIKLY’s over the last 12 months.

GRFS's Price Growth Rating (53) in the Pharmaceuticals Major industry is in the same range as GIKLY (57) in the null industry. This means that GRFS’s stock grew similarly to GIKLY’s over the last 12 months.

GIKLY's P/E Growth Rating (94) in the null industry is in the same range as GRFS (95) in the Pharmaceuticals Major industry. This means that GIKLY’s stock grew similarly to GRFS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GIKLYGRFS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
65%
Bearish Trend 3 days ago
68%
Momentum
ODDS (%)
Bullish Trend 3 days ago
57%
Bearish Trend 3 days ago
73%
MACD
ODDS (%)
Bullish Trend 3 days ago
57%
Bullish Trend 3 days ago
72%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
53%
Bullish Trend 3 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
57%
Bullish Trend 3 days ago
71%
Advances
ODDS (%)
N/A
Bullish Trend 6 days ago
69%
Declines
ODDS (%)
N/A
Bearish Trend 12 days ago
78%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
GIKLY
Daily Signal:
Gain/Loss:
GRFS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CBLS27.920.02
+0.06%
Clough Hedged Equity ETF
JMHI50.370.02
+0.04%
JPMorgan High Yield Municipal ETF
TRPA39.060.01
+0.03%
Hartford AAA CLO ETF
AOD9.98N/A
N/A
abrdn Total Dynamic Dividend Fund
CPSJ26.91-0.01
-0.02%
Calamos S&P 500 Str Alt Prt ETF-Jul

GIKLY and

Correlation & Price change

A.I.dvisor indicates that over the last year, GIKLY has been closely correlated with GRFS. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GIKLY jumps, then GRFS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GIKLY
1D Price
Change %
GIKLY100%
N/A
GRFS - GIKLY
68%
Closely correlated
+0.78%
GIFOF - GIKLY
27%
Poorly correlated
N/A
GIFLF - GIKLY
25%
Poorly correlated
N/A
ORINY - GIKLY
9%
Poorly correlated
N/A
OPHLY - GIKLY
8%
Poorly correlated
-0.15%
More

GRFS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRFS has been closely correlated with GIKLY. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GRFS jumps, then GIKLY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
+0.78%
GIKLY - GRFS
68%
Closely correlated
N/A
GIFOF - GRFS
37%
Loosely correlated
N/A
GILD - GRFS
29%
Poorly correlated
-0.77%
PFE - GRFS
28%
Poorly correlated
+0.24%
BIIB - GRFS
28%
Poorly correlated
+0.43%
More